Inflection Biosciences Ltd.

Innovative drug therapies. Focusing on small molecular therapeutics with big impact for patients and investors in cancer, autoimmune and inflammatory diseases.

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences Ltd today announced that new data on IBL-101, a pan-PIM kinase inhibitor, will be highlighted in a poster presentation at the British Society for Immunology Congress 2022 taking place from December 5-8, 2022 in Liverpool, U.K.

https://t.co/gEt31uaypX

[Inflection Biosciences Ltd. @InflectionBio]

@Innoplexus and @InflectionBio enter strategic collaboration based on Artificial Intelligence.

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences broadens knowledge pool into autoimmune and inflammatory disease, by adding immunology and rheumatology expertise and advisory panel.

Visit https://t.co/N820j4akd1 to know more.

[Inflection Biosciences Ltd. @InflectionBio]

Well done to all, & our partners at @CNIOStopCancer, in achieving publication in ACS Medicinal Letters describing the discovery of AUM302, a first-in-class PIM/PI3K/mTOR inhibitor in late pre-clinical development for the treatment of unmet needs in cancer.
https://t.co/9h6pwKpOhL

[Inflection Biosciences Ltd. @InflectionBio]

We are pleased to collaborate with Gain Hahn, The Glasgow School of Art, and Dr Tony McElligott at Trinity St James’s Cancer Institute in producing this animation for the unique mechanism of action of our PIM/PI3K inhibitor IBL-202.
https://t.co/FsIrmC3PNx

[Inflection Biosciences Ltd. @InflectionBio]

Looking forward to meeting industry colleagues virtually at Bio-Europe later this month. Always a great opportunity to provide updates on our research programs in oncology, inflammation/autoimmune.
#bioeurope #inflammation #cancerresearch #rheumatoidarthritis #psoriasis

[Inflection Biosciences Ltd. @InflectionBio]

A further publication supporting the rationale for co-targeting PIM/PI3K/mTOR inhibition to treat unmet needs in NSCLC. @InflectionBio licensed IBL-300/AUM300 to @AumBiosciences in 2019. Well done to @kathygately1 and all the authors on achieving this.
https://t.co/nsdpKaOj00

[European Innovation Council @EUeic]

The first day of the #EUeic Investor Day on Health has brought together 2️⃣5️⃣ #SMEs and 1️⃣6️⃣ investors for an epitching showdown in the topics of:

💻 eHealth
🩺 Medtech
🔬 Biotech

Good luck 🍀 to all our beneficiaries and stay tuned to learn more!

#eicAccelerator

[Inflection Biosciences Ltd. @InflectionBio]

Good review here setting out the rationale and need for dual targeting of different survival pathways in cancer to improve treatment outcomes and to reduce the risk of relapses. Good to see Inflection Biosciences' molecules included in the review. #biotech
https://t.co/EffAXkfKsg

[Blood Advances @BloodAdvances]

IBL-202 is synergistic with venetoclax in #CLL under in vitro conditions that mimic the tumor microenvironment https://t.co/Qu9FnlJLst

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences is Pleased to Announce Publication of Positive Pre-clinical Data for IBL-202, a PIM/PI3K Inhibitor, in Chronic Lymphocytic Leukemia.

Read more at https://t.co/9pBzpZeZSt

[Inflection Biosciences Ltd. @InflectionBio]

Delighted to welcome Greg Berk, MD, to our Board. Greg brings over 30 years of cancer drug development and regulatory expertise having worked in a number of U.S. oncology biotechs including Verastem, Sideris, Intellikine (acquired by Takeda) and Abraxis (acquired by Celgene).

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences Ltd. Announces Publication of Positive Data for IBL-202, a PIM/PI3K Inhibitor in Diffuse Large B-cell Lymphoma.

Read about it here : https://t.co/QkrR8N1brN

[DCU School of Biotechnology @DcuBiotech]

New article featuring @nicb_dcu researcher @Dr_Alex_Eustace and colleagues from @RCSI_Irl and @InflectionBio detailing their recent publication in which they trialed a potential new treatment toward #breastcancer

More at the following link: https://t.co/GK5CcEqMwv

[Inflection Biosciences Ltd. @InflectionBio]

We're pleased to announce the appointment of Professor Martin Dreyling to our Oncology Advisory Panel.

Read more about it at - https://t.co/eEhdQNIL0R

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences’ Chief Scientific Officer, Shaun McNulty discusses the scientific rationale underpinning IBL-202.

Visit https://t.co/RvyTsViXiY to know more about IBL-202.

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences Ltd. is happy to announce that it will participate in three upcoming virtual investor and partnering conferences.

Contact us at [email protected] to arrange a virtual meeting.

@SachsAssociates #Sachs_IOIF #Inflection #biointernationalconvention #resi

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences CEO, Darren Cunningham sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference held in NYC on February 2020.

@christicorrado @proactive_NA
https://t.co/SaGvTbg94Y via @YouTube

[Inflection Biosciences Ltd. @InflectionBio]

We're pleased to announce the release of our new website, designed with a fresh new look to provide our visitors with an easier way to learn about us.

Visit https://t.co/N820j4rV4z to check us out.

[Inflection Biosciences Ltd. @InflectionBio]

Inflection Biosciences and AUM Biosciences announce Global License Agreement for PIM/PI3K/mTOR inhibitors https://t.co/oTMnLExfWS